Trial document





This trial has been registered retrospectively.
drksid header

  DRKS00008587

Trial Description

start of 1:1-Block title

Title

Healthcare research multiple myeloma (MM) - parameters to be assessed within the evaluation of the MM-Tumorboard (TB).

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The MM-TB was initiated in 06/2012. Therein, physicians and referring oncologists present and discuss difficult-to-treat MM patients. It's an interdisciplinary conference (hematology/oncology, orthopedics, pathology, radiation therapy, cytogenetics; according to question: cardiology, nephrology, Comprehensive Cancer Care(CCCF)), which is held weekly, each monday, 4-5 pm. The goal is to provide a best possible patient care. In this study we want to search for parameters to be assessed within the evaluation of the MM-TB. This analysis focused on a) discussed TB questions, b) given recommendations and c) patient characteristics.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The MM-TB was initiated in 06/2012. t's an interdisciplinary conference with hematology/oncology, orthopedics, pathology, radiation therapy, cytogenetics and according to question: cardiology, nephrology and Comprehensive Cancer Care(CCCF). The goal is to provide a best possible patient care. This analysis focused on a) discussed TB questions, b) given recommendations and c) patient characteristics.
Grades of recommendations were assigned using the GRADE criteria (Engelhardt M. Haematologica 2014) and meticulously assessed, as well as whether TB recommendations were pursued.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00008587
  •   2015/05/29
  •   [---]*
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C90.0 -  Multiple myeloma
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   The tunorboard (TB) for patients with multiple myeloma (MM) was initiated in 06/2012. t's an interdisciplinary conference with hematology/oncology, orthopedics, pathology, radiation therapy, cytogenetics and according to question: cardiology, nephrology and Comprehensive Cancer Care(CCCF). The goal is to provide a best possible patient care. This analysis focused on a) discussed TB questions, b) given recommendations and c) patient characteristics.
    Grades of recommendations were assigned using the GRADE criteria (Engelhardt M. Haematologica 2014) and meticulously assessed, as well as whether TB recommendations were pursued.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Health care system
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

a. discussed tumorboard-questions
b. given recommendations
c. parameters to be assessed within the evaluation of the tumorboard for patients with multiple myeloma (patient characteristics)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

none

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2014/03/03
  •   299
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   no minimum age
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Patients with multiple myeloma presented and discussed at the tumorboard.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

none.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Uniklinik Freiburg
    • Ms.  Prof. Dr. med.  Monika Engelhardt  Engelhardt 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Uniklinik Freiburg
    • Ms.  Prof. Dr. med.  Monika Engelhardt  Engelhardt 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Uniklinik Freiburg
    • Ms.  Prof. Dr. med.  Monika Engelhardt  Engelhardt 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Uniklinik Freiburg
    • Ms.  Prof. Dr. med.  Monika Engelhardt  Engelhardt 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.